Regulatory Approval

Regulatory Approval

Eco Animal Health Group Plc

ECO Animal Health Group plc

(AIM: EAH)

ECO RECEIVES MARKETING AUTHORISATION FOR AIVLOSIN® FOR CHICKENS LAYING EGGS FOR HUMAN CONSUMPTION IN EGYPT

ECO Animal Health Group plc (“ECO”) is pleased to announce that it has received a marketing authorisation from the Drug Authority of the Ministry of Health of Egypt for the use of Aivlosin® 625 mg/g water soluble granules in chickens laying eggs for human consumption.

This approval allows ECO to start selling Aivlosin® in Egypt for the medication of drinking water for the treatment of infections caused by Mycoplasma in poultry laying eggs for human consumption, with a zero day drug withdrawal period for eggs.

ECO has begun the process of submitting the EU approved Aivlosin® regulatory files for the treatment of layers in numerous other key egg producing markets.

Aivlosin^®, ECO’s patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

Peter Lawrence, Chairman of ECO, commented “Egypt is the second most important egg producing country in the Middle East and is ranked just outside the global top twenty for commercial layers. This latest approval demonstrates ECO’s continued progress towards becoming a major force in the international market for veterinary pharmaceutical products for livestock.”

Contacts:

ECO Animal Health Group plc

Peter Lawrence	Â	Â	Â	020 8336 6190
Marc Loomes				020 8447 6906
Spiro Financial
Anthony Spiro				020 8336 6196
Peel Hunt LLP (Nominated Adviser)
Dan Webster, Adrian Trimmings, George Sellar				020 7418 8900
N+1 Singer (Joint Broker)				020 7496 3000
Mark Taylor, Brough Ransom
					Â

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170820005010/en/